Clasp Therapeutics vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clasp Therapeutics develops tumor-specific T cell engagers targeting mutant p53 and other cancer driver mutation peptides presented by HLA molecules, enabling precise solid tumor immunotherapy.
About
Clasp Therapeutics is a clinical-stage immuno-oncology company developing precision T cell engagers (TCEs) that direct the immune system to destroy solid tumors harboring common oncogenic driver mutations. Unlike first-generation TCEs that target proteins shared between tumor and healthy cells, Clasp''s bispecific antibodies recognize tumor-specific peptide-HLA complexes — molecular fingerprints unique to cancer cells created by mutated proteins.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.